资金流向方面，今日该股主力资金净流入4062.18万元，其中，特大单净流入4471.16万元，大单资金净 流出408.98万元。近5日主力资金净流入9911.78万元。（数据宝） 民生健康11月14日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 深股通专用 | 2393.91 | 2367.30 | | 买二 | 机构专用 | 2013.49 | 1726.92 | | 买三 | 机构专用 | 1980.71 | 1282.13 | | 买四 | 机构专用 | 1937.24 | 1551.83 | | 买五 | 华泰证券股份有限公司北京东三环北路证券营业部 | 1438.29 | 3.71 | | 卖一 | 深股通专用 | 2393.91 | 2367.30 | | 卖二 | 机构专用 | 2013.49 | 1726.92 | | 卖三 | 机构专用 | 1937.24 | 1551.83 | | 卖四 | 机构专用 | 1216.47 | 1456.22 | | 卖五 | 招商证券股份有限公 ...

Summary of Minsheng Health Conference Call Industry and Company Overview - **Company**: Minsheng Health - **Industry**: Health and Wellness, specifically focusing on OTC vitamins and minerals, and health supplements Key Financial Highlights - **Q3 2025 Revenue**: 160 million CNY, up 31% year-over-year [2][5] - **Net Profit**: 32 million CNY, up 259% year-over-year [2][5] - **Cumulative Revenue for First Three Quarters**: 600 million CNY, up 20% year-over-year [2][5] - **Cumulative Profit**: 114 million CNY, up 33% year-over-year [2][5] - **Gross Margin**: Approximately 46%, down 2% year-over-year due to product mix changes [2][6] Product Segmentation and Performance - **Main Business Segments**: - OTC Vitamins and Minerals (e.g., 21 Jin Weita) - 70% - Blue Hat Health Products - 30% [2][6] - **Growth Rate of Vitamin and Mineral Products**: Close to 10%, aligning with annual guidance [2][6] - **E-commerce Impact**: Significant growth in online sales post-pandemic, with self-paid health products outpacing offline OTC products [2][7] New Product Developments - **Launch of Smoking Cessation Drug "Lesuoke"**: - Active Ingredient: Varenicline Tartrate - Pricing: 99 CNY for the starter pack, 189 CNY for the maintenance pack [3] - Estimated Treatment Cost: Approximately 2,178 CNY for a complete 12-week course [3] - Projected Revenue Contribution for 2026: Conservative estimate of 50 million CNY, optimistic estimate of 100 million CNY [3][4] - **Proposed Functional Probiotics**: Plans to introduce products targeting weight loss, sleep improvement, and gut health [11] Future Growth Strategies - **Focus Areas**: - Continue to drive new product cycles, particularly with Lesuoke - Strengthen e-commerce channel development [8] - **Long-term Vision**: Aim for a market capitalization of 10 billion CNY by the company's centennial in 2026 [8] Competitive Advantages - **R&D Capabilities**: Strong research and development capabilities, with a mature process for obtaining regulatory approvals [9] - **Parent Company Support**: The controlling shareholder is also a pharmaceutical company, providing a competitive edge in R&D [9] Market Trends and Projections - **2025 Revenue Projection**: Expected to reach 798 million CNY, a 24% increase year-over-year [13] - **Profit Projection**: Anticipated profit of 127 million CNY, a 38% increase year-over-year [13] - **Future Product Launches**: Plans to enter the medical aesthetics market with new products like Minoxidil [14]

Core Viewpoint - Minsheng Health (301507) reported that the overall gross margin fluctuations are primarily influenced by product structure and distribution channels, with no cost-related factors affecting gross margin levels [1] Group 1: Product Performance - The vitamin and mineral category constitutes the highest revenue share for the company, with the main product, 21 Jin Weita Multi-element Tablets, maintaining a normal gross margin level [1] - Within the vitamin and mineral category, various subcategories exhibit differing gross margins due to diverse sales models [1] Group 2: Market Trends - The growth rate of vitamin and mineral health foods and functional foods has outpaced that of vitamin and mineral OTC products over the past two years, contributing to a decline in overall gross margin [1] Group 3: Future Outlook - The company anticipates that the gross margin will gradually improve with the increase in sales scale of new products and the expansion of self-operated business, particularly in the probiotics and therapeutic drug segments, which currently have higher gross margins [1]

Core Viewpoint - Minsheng Health (301507) announced that the acquisition of Zhongke Jiayi has effectively driven business growth through brand synergy and influence [1] Group 1: Business Growth and Partnerships - Zhongke Jiayi has established cooperative relationships with leading domestic health food OEMs and milk powder companies, leveraging the brand influence and customer channel advantages of the listed company [1] - The business performance of Zhongke Jiayi aligns with expectations as it continues to deepen strain research and industrial applications [1] Group 2: Future Projects and Opportunities - The "Armor Probiotic Intelligent Manufacturing Upgrade Project" was officially launched by Zhongke Jiayi, expected to bring opportunities in terms of products, costs, efficiency, and market by the end of September 2025 [1] - The company is actively expanding into cutting-edge fields such as weight management, gut-brain axis, and metabolic health [1]

Core Viewpoint - Minsheng Health (301507) announced that the domestic approval for varenicline tablets was mostly obtained in recent years, and related companies have just begun sales, with scale gradually increasing [1] Group 1: Market Potential - The report from the National Health Commission indicates a large number of smokers in China, suggesting significant market space for smoking cessation drugs [1] - The market potential for varenicline in China has not been fully developed, referencing Pfizer's original drug sales performance in overseas markets [1] Group 2: Collaboration and Initiatives - The company collaborates with authoritative smoking cessation organizations to conduct public education on smoking cessation [1] - In August 2025, the company, in partnership with the China Smoking Control Association, will release the "China Clinical Smoking Control and Cessation Expert Consensus Gold Standard (2025 Updated Version)" [1] - In November 2025, the company will jointly establish a Health Promotion Professional Committee with the China Smoking Control and Health Association [1] Group 3: Commitment to Public Health - As an active participant in public health services, the company plans to collaborate with relevant authoritative institutions to promote academic research, standard formulation, and health education [1] - The company aims to contribute to the establishment of a more comprehensive smoking control system, supporting the construction of a healthy China through its pharmaceutical efforts [1]

证券日报网讯民生健康（301507）11月13日发布公告，在公司回答调研者提问时表示，公司已成功在陕 西西安、辽宁沈阳、湖北黄石、山西太原等地开设样板店，后续也会陆续推进更多样板店的建设。目前 主要对现有门店的运营进行持续跟踪评估，现阶段更关注的是运营模式的优化和客户体验的提升，根据 实际情况及时调整相关策略，扎实打磨，为未来发展打好基础。 ...

Core Viewpoint - Minsheng Health (301507) announced on November 13 that its new products, including Minsheng Lesuke Tartrate Varenicline Tablets and Minsheng Xunfa Minoxidil Lotion, are currently in the early stages of market launch, and there are no sales data available yet [1] Group 1 - The company indicated that the launch of new products will involve certain cost allocations, but it is expected that this will not significantly impact the overall sales expense ratio and profit situation [1]

证券日报网讯民生健康（301507）11月13日发布公告，在公司回答调研者提问时表示，通过产品品类的 拓展及渠道的拓宽与深耕，公司维生素矿物质系列产品整体保持稳健增长。 ...

南财智讯11月13日电，民生健康在投资者关系活动中表示，收购中科嘉亿后，借助上市公司的品牌影响 力和客户渠道优势，中科嘉亿已与国内头部保健食品代工企业、乳粉企业等大客户逐步建立合作关系， 业务实现有效增长。2025年9月底，中科嘉亿"盔甲益生菌智造升级项目"已正式启动，新产线将在产 品、成本、效率和市场方面为公司未来发展带来积极影响。公司持续深化菌株研发与产业应用，积极拓 展体重管理、肠脑轴、代谢健康等前沿领域，整体业务表现符合预期。 ...

Company Overview - The company introduced its development history, main business segments, and products during the investor relations activity [1]. Financial Performance - The main product line, the vitamin and mineral series, has shown steady growth through product category expansion and channel development [2]. - The overall gross margin has fluctuated due to product structure and channel influences, with vitamin and mineral products being the highest revenue contributors [3][4]. - The growth rate of vitamin and mineral health foods has outpaced that of functional foods, leading to a decline in overall gross margin [4]. Business Development - The acquisition of Zhongke Jiayi has positively impacted the probiotics business, leveraging brand synergy and establishing partnerships with major clients in the health food sector [2]. - The "Armor Probiotics Intelligent Manufacturing Upgrade Project" was launched at the end of September 2025, aimed at enhancing product, cost, efficiency, and market aspects [2]. Market Opportunities - The market potential for smoking cessation products, particularly Varenicline, is significant due to the large number of smokers in China, with sales expected to grow as awareness increases [2]. - The company collaborates with authoritative smoking cessation organizations to promote public health education and research [2]. Product Development - New products like Minsheng Lesuke and Minsheng Xunfa are in the early stages of market entry, with no sales data available yet [4]. - The company anticipates that initial consumer education for new products will require investment but will not significantly impact overall sales expense ratios or profit levels [4]. Future Plans - The company plans to continue expanding its sample store network in various cities, focusing on optimizing operational models and enhancing customer experience [2].